- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2490
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
CALN1 hypomethylation as a biomarker for high-risk bladder cancer ; volume:22 ; number:1 ; day:9 ; month:11 ; year:2022 ; pages:1-8 ; date:12.2022
BMC urology ; 22, Heft 1 (9.11.2022), 1-8, 12.2022
- Urheber
-
Takagi, Kimiaki
Naruse, Azumi
Akita, Kazutoshi
Muramatsu-Maekawa, Yuka
Kawase, Kota
Koie, Takuya
Horie, Masanobu
Kikuchi, Arizumi
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12894-022-01136-y
- URN
-
urn:nbn:de:101:1-2023012321513576067452
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:37 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Takagi, Kimiaki
- Naruse, Azumi
- Akita, Kazutoshi
- Muramatsu-Maekawa, Yuka
- Kawase, Kota
- Koie, Takuya
- Horie, Masanobu
- Kikuchi, Arizumi
- SpringerLink (Online service)
Ähnliche Objekte (12)
C14orf166 is a high-risk biomarker for bladder cancer and promotes bladder cancer cell proliferation
DNA hypomethylation and gene expression in bladder cancer
Bladder cancer course, four genetic high-risk variants, and histopathological findings
PAX1 hypomethylation as a prognostic biomarker for radioresistance of cervical cancer
Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer
Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer
Intravesical thermochemotherapy in the treatment of high-risk and very high-risk non-muscle-invasive urothelial bladder cancer: a single-arm study
High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG Shortage
Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer
Risk score-based substratification improves surveillance costs after transurethral resection of bladder tumor in patients with primary high-risk non-muscle-invasive bladder cancer
Understanding high-risk business
HSF1 is a novel prognostic biomarker in high-risk prostate cancer that correlates with ferroptosis
C14orf166 is a high-risk biomarker for bladder cancer and promotes bladder cancer cell proliferation
DNA hypomethylation and gene expression in bladder cancer
Bladder cancer course, four genetic high-risk variants, and histopathological findings
PAX1 hypomethylation as a prognostic biomarker for radioresistance of cervical cancer
Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer
Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer
Intravesical thermochemotherapy in the treatment of high-risk and very high-risk non-muscle-invasive urothelial bladder cancer: a single-arm study
High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG Shortage
Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer
Risk score-based substratification improves surveillance costs after transurethral resection of bladder tumor in patients with primary high-risk non-muscle-invasive bladder cancer
Understanding high-risk business
HSF1 is a novel prognostic biomarker in high-risk prostate cancer that correlates with ferroptosis
C14orf166 is a high-risk biomarker for bladder cancer and promotes bladder cancer cell proliferation
DNA hypomethylation and gene expression in bladder cancer
Bladder cancer course, four genetic high-risk variants, and histopathological findings
PAX1 hypomethylation as a prognostic biomarker for radioresistance of cervical cancer
Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer
Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer
Intravesical thermochemotherapy in the treatment of high-risk and very high-risk non-muscle-invasive urothelial bladder cancer: a single-arm study
High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG Shortage
Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer
Risk score-based substratification improves surveillance costs after transurethral resection of bladder tumor in patients with primary high-risk non-muscle-invasive bladder cancer
Understanding high-risk business